Publications by authors named "R Laddach"
Article Synopsis
- Anti-EGFR antibodies have limited effectiveness in breast cancer due to compensatory pathways and resistance in triple-negative breast cancer (TNBC) from CDK2/cyclin E expression; however, a cetuximab-based antibody drug conjugate (ADC) incorporating a CDK inhibitor may improve targeted treatment.
- In experimental designs, researchers evaluated the expressions of cell cycle regulators alongside EGFR and developed an ADC, combining cetuximab with CDK inhibitor SNS-032, to specifically deliver treatment to EGFR-expressing cancer cells.
- Results showed that the ADC effectively inhibited tumor growth, induced cytotoxic effects on high EGFR-expressing cells, and demonstrated potential for improved targeting in aggressive breast cancer types, highlighting the importance
Article Synopsis
- - B cells play a crucial role in the immune response against tumors, particularly in melanoma, but their specific functions and characteristics have not been fully explored until now.
- - In this study, researchers found that memory B cells are more prevalent in tumors than in the bloodstream and exhibit unique antibody profiles that indicate processes like clonal expansion and affinity maturation.
- - The presence of tumor-associated B cells with autoimmune-like traits and high levels of antibodies related to both autoimmune diseases and cancer suggests a dysregulated immune response in melanoma patients.
Article Synopsis
- Despite existing checkpoint inhibitor therapies, about half of melanoma patients still struggle with poor outcomes.
- A new engineered monoclonal IgE antibody targeting the CSPG4 antigen shows promise by binding to melanoma cells and enhancing immune responses.
- In studies, this IgE therapy significantly improved survival and anti-tumor activity in models, suggesting its potential as an effective treatment option for melanoma patients.
Background: Survival rates for ovarian cancer remain poor, and monitoring and prediction of therapeutic response may benefit from additional markers. Ovarian cancers frequently overexpress Folate Receptor alpha (FRα) and the soluble receptor (sFRα) is measurable in blood. Here we investigated sFRα as a potential biomarker.
View Article and Find Full Text PDF